Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanale, Daniele, Amodeo, Valeria, Bazan, Viviana, Insalaco, Lavinia, Incorvaia, Lorena, Barraco, Nadia, Castiglia, Marta, Rizzo, Sergio, Santini, Daniele, Giordano, Antonio, Castorina, Sergio, Russo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045398/
https://www.ncbi.nlm.nih.gov/pubmed/27081088
http://dx.doi.org/10.18632/oncotarget.8722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045398/
https://www.ncbi.nlm.nih.gov/pubmed/27081088
http://dx.doi.org/10.18632/oncotarget.8722

Ejemplares similares